Inheritance and drug response

New England Journal of Medicine

Volumn 348, Issue 6, 2003, Pages 529-537

  Weinshilboum, Richard ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; HYDRALAZINE; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; ISONIAZID; LEVODOPA; LOSARTAN; METOPROLOL; MUSCLE RELAXANT AGENT; NORTRIPTYLINE; OMEPRAZOLE; PHENYTOIN; PROCAINAMIDE; SPARTEINE; SUXAMETHONIUM; TUBERCULOSTATIC AGENT; WARFARIN;

ACETYLATOR PHENOTYPE; ACUTE LYMPHOBLASTIC LEUKEMIA; APNEA; BONE MARROW SUPPRESSION; DRUG ACETYLATION; DRUG CONJUGATION; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; INHERITANCE; NEUROTOXICITY; OTOTOXICITY; PARALYSIS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE;

EID: 0037421584     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra020021     Document Type: Review

References (67)

1. Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: W.B. Saunders, 1962.
2. Price Evans DA. Genetic factors in drug therapy: clinical and molecular pharmacogenetics. Cambridge, England; Cambridge University Press, 1993.
3. Weber WW. Pharmacogenetics. New York: Oxford University Press, 1997.
4. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
5. Wilkinson GR. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:3-29.
6. Ross EM, Kenakin TP. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:31-43.
7. Kalow W. The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture: pharmacogenetics; past and future. Life Sci 1990;47:1385-97.
8. Kalow W, Gunn DR. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet 1959;23:239-50.
9. Idem. The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther 1957;120:203-14.
10. Price Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960;2:485-91.
11. Timbrell JA, Harland SJ, Facchini V. Polymorphic acetylation of hydralazine. Clin Pharmacol Ther 1980;28:350-5.
12. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 1975;17:722-30.
13. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977;22:251-8.
14. Kroemer HK, Eichelbaum M. "It's the genes, stupid": molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56:2285-98.
15. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
16. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
17. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97. [Erratum, Clin Pharmacol Ther 1994;55:648.]
18. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-9.
19. Gonzalez FJ, Vilbois F, Hardwick JP, et al. Human debrisoquine 4-hydroxylase (P450IID1): CDNA and deduced amino acid sequence and assignment of the CYP2D locus of chromosome 22. Genomics 1988;2:174-9.
20. Kimura S, Umeno M, Skoda R, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989;45:889-904.
21. Ingelman-Sundberg M, Evans WE. Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics 2001;11:553-4.
22. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers ofdebrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-6.
23. Dalén P, Dahl ML, Ruiz MLB, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444-52.
24. Stubbins MJ, Harris LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-39.
25. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
26. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
27. Mortimer O, Persson K, Ladona MG, et al. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 1990;47:27-35.
28. Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995;5:335-46.
29. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.
30. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 2001;70:159-64.
31. van der Weide J, Steijns LSW, van Weelden MJM, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001;11:287-91.
32. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001;70:391-4.
33. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
34. Balian J, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
35. Tybring G, Böttiger Y, Widén J, Bertilsson L. Enantioselective hydroxylatìon of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997;62:129-37.
36. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rate for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-30.
37. Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999;66:528-34.
38. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site ofintron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001;7:2832-9.
39. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinurea associated with severe fluorouracil toxicity. N Engl J Med 1985;313:245-9.
40. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81:47-51.
41. Lockridge O. Genetic variants of human butyrylcholinesterase influence the metabolism of the muscle relaxant succinylcholine. In: Kalow W, ed. Pharmacogenetics of drug metabolism. International encyclopedia of pharmacology and therapeutics. New York: Pergamon Press, 1992:15-50.
42. McGuire MC, Nogueira CP, Bartels CF, et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form ofhuman serum cholinesterase. Proc Natl Acad Sci U S A 1989;86:953-7.
43. McLeod HL, Collie-Duguid ESR, Vreken P, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998;8:455-9.
44. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyl-transferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
45. Lin HJ, Han C-Y, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993;52:827-34.
46. Price Evans DA. N-acetyltransferase in pharmacogenetics of drug metabolism. In: Kalow W, ed. Pharmacogenetics of drug metabolism. International encyclopedia of pharmacology and therapeutics. New York: Pergamon Press, 1992;43:95-178.
47. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
48. Remy CN. Metabolism of thiopyrimidines and thiopurines: S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem 1963;238:1078-84.
49. Woodson LC, Weinshilboum R.M. Human kidney thiopurine methyltransferase: purification and biochemical properties. Biochem Pharmacol 1983;32:819-26.
50. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
51. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999;39:19-52.
52. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
53. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
54. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
55. Tai H-L, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
56. Tai H-L, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 1997;94:6444-9.
57. Collie-Duguid ESR, Pritchard SC, Powrie PH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
58. Dufour AP, Knight RA, Harris HW. Genetics of isoniazid metabolism in Caucasian, Negro, and Japanese populations. Science 1964;145:391.
59. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999;9:341-9.
60. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999;9:591-9.
61. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999;65:576-82.
62. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
63. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenetics 2002;2:43-7.
64. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet 1977;29:125-35.
65. Reilly DK, Rivera-Calimlim L, Van Dyke D. Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 1980;28:278-86.
66. Lander ES, Linton LM, Birren B, et al. initial sequencing and analysis of the human genome. Nature 2001;409:860-921. [Errata, Nature 2001;411:720, 412:565.]
67. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-51. [Erratum, Science 2001;292:1838.]